Nuvectis Pharma, Inc. (NASDAQ: NVCT) announced the pricing of its previously announced underwritten public offering of 5 million shares of common stock at $20.00 per share, generating expected gross proceeds of approximately $100 million. The company also granted the underwriters a 30-day option to purchase up to an additional 750,000 shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about July 1, 2026, subject to customary closing conditions.
Nuvectis said it intends to use the net proceeds to advance development of its NXP100, NXP200 and NXP900 programs, support future product candidates, hire additional personnel, fund capital expenditures and cover general corporate purposes. Cantor is serving as sole book-running manager, with H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners and Titan Partners acting as co-managers.
To view the full press release, visit https://ibn.fm/SrZnr.
Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The Company’s pipeline includes NXP100, a complement Factor B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP900 and NXP200, in development for the treatment of advanced cancers.
NXP100 is a late-stage Factor B inhibitor with best-in-class potential as an effective therapy in multiple complement-mediated diseases and provide a convenience advantage as the only once-daily oral treatment option for these diseases requiring life-long treatment. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases, including SRC and YES1 intended to inhibit the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the signaling pathway. NXP200 is an oral, brain penetrant, paradox-breaker BRAF inhibitor for the treatment of BRAF V600X-mutated and Class II/III non-V600-mutated solid tumor malignancies, including central nervous system cancer, colorectal cancer, melanoma, and non-small cell lung cancer, with best-in-class potential.
For more information, visit https://nuvectis.com/.
The significance of this capital raise lies in its potential to accelerate the development of Nuvectis's promising pipeline, which targets both complement-mediated diseases and oncology. With approximately $100 million in gross proceeds, the company can fund key clinical trials and potentially bring new treatment options to patients. For investors, the offering provides insight into the company's financial strategy and confidence in its programs. However, the dilutive nature of the offering may affect existing shareholders. The success of these programs could have a substantial impact on the biopharmaceutical industry, particularly in areas of high unmet medical need such as complement diseases and advanced cancers.
